All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Business Development & Partnerships

AbbVie acquires Gilgamesh's psychedelic drug program bretisilocin for up to $1.2B, including upfront fee and milestones
Acquisition, psychedelic drug, neurological, milestone payments, psychiatric disorders, drug discovery - Read more

Royalty Pharma acquires BeOne's stake in Amgen's lung cancer drug Imdelltra for $885M upfront, potential $950M total
Acquisition, oncology, royalties, small molecule, lung cancer, milestone payments - Read more

Bio-Thera and STADA expand biosimilars partnership to include tocilizumab, giving STADA exclusive commercialization rights in Europe and beyond
Licensing deal, biosimilars, autoimmune, antibody, commercialization - Read more

Apimeds partners with University of Alabama on ai² Future Labs program to develop abandoned pharmaceutical projects and train future industry leaders
Research collaboration, drug discovery, R&D, business development, academic partnership - Read more

PRESENTED BY PROMOVEO HEALTH
Contract Sales Reps. Half the Budget. Double the Impact.

Stretching your commercial budget?

Get two flex-time reps for the price of one full-time with Promoveo Health.

We build agile field teams that scale up or down based on your brand’s needs — fast.

See how flexible can work - click here to learn more.

✅ More Good News ✅

THE GOOD
Clinical Trials

Akeso reports Ph3 wins for gumokimab (IL-17A) in ankylosing spondylitis and manfidokimab (IL-4Rα) in atopic dermatitis
Antibody, autoimmune, monoclonal antibody, atopic dermatitis, ankylosing spondylitis, IL-17A target - Read more

PDS Biotech's PDS0101-Keytruda combo shows 39-month survival benefit in Ph2 head and neck cancer trial
Vaccine, cancer, therapeutic cancer vaccine, head and neck cancer, immunotherapy, HPV16, PD-1 inhibitor - Read more

Argenx's Vyvgart succeeds in Ph3 trial, plans FDA filing for seronegative generalized myasthenia gravis
Antibody, autoimmune, FcRn inhibitor, myasthenia gravis, rare disease, label expansion - Read more

Lundbeck's bexicaserin shows 59.3% seizure reduction in Ph1b/2a trial for developmental and epileptic encephalopathies
Small molecule, neurological, epilepsy, developmental and epileptic encephalopathies, seizure reduction - Read more

jCyte's Ph1/2a trial demonstrates safety of retinal progenitor cells for retinitis pigmentosa treatment
Cell therapy, neurological, retinal progenitor cells, retinitis pigmentosa, ophthalmology - Read more

THE GOOD
Company Launches

Arnatar Therapeutics debuts with $52M Series A, developing RNA-based therapeutics for genetic diseases
Antisense oligonucleotide, rare disease, genetic disease, RNA-based therapeutics, translation-enhancing platform - Read more

THE GOOD
Earnings & Finances

Merck & Co. eyes $5B HIV portfolio with new treatment applications amid Keytruda patent concerns
Small molecule, infectious disease, strategic, financial - Read more [Paywall]

THE GOOD
Fundraises

Vaxxas raises ~A$90M ($58.4M) Series D, commercializing needle-free vaccine delivery technology
Vaccine delivery, needle-free technology, platform technology, medical device, manufacturing - Read more

Incyclix Bio raises $11.25M Series B extension for CDK2 inhibitor cancer treatment
Oncology, small molecule, cancer, clinical-stage, CDK inhibitor, precision medicine - Read more

BriaCell receives $2M NCI grant to develop Bria-PROS+ prostate cancer immunotherapy
Oncology, immunotherapy, prostate cancer, cell therapy, clinical-stage - Read more

THE GOOD
Investments

Genentech begins construction on $700M North Carolina manufacturing facility for obesity drugs, adding 400 jobs
Metabolic medicine, obesity, manufacturing investment, onshoring, strategic, operational - Read more

THE GOOD
Mergers & Acquisitions

MannKind acquires scPharmaceuticals for $360M, adding heart failure treatment Furoscix to cardiometabolic portfolio
Subcutaneous infuser, cardiovascular, major transaction, strategic acquisition, cardiometabolic - Read more

Terumo acquires OrganOx for $1.5B, expanding into organ transplantation with specialized preservation technology
Organ preservation devices, transplantation, strategic, major transaction, medical technology - Read more

THE GOOD
Product Launches

Eisai, Biogen launch Alzheimer's drug LEQEMBI in Austria and Germany, marking first EU market entries
Monoclonal antibody, neurological, regulatory, market expansion, Alzheimer's disease - Read more

THE GOOD
Regulatory

FDA approves Coya Therapeutics' IND application for COYA 302, triggering $4.2M payment from Dr. Reddy's
Immunotherapy, neurological disease, regulatory, milestone payment - Read more

PRESENTED BY YOU?
Get the attention of 2000+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Company Shutdown

Appia Bio, CAR-T cell therapy startup with Kite partnership, shuts down after exhausting $52M funding
Cell therapy, oncology, research collaboration, funding constraints - Read more

THE BAD
Politics & Policy

HHS moves to de-recognize employee unions, removing collective bargaining rights amid legal battles and criticism
Government policy, regulatory, operational, labor relations - Read more

THE UGLY
Regulatory

FDA suspends Valneva's chikungunya vaccine license over serious safety concerns including death from vaccine-derived infection
Live attenuated vaccine, infectious disease, regulatory, safety concerns - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here